The Minister of Health, Onyebuchi Chukwu, on Tuesday in Bauchi granted regulatory approval for the production of newborn cord care antiseptic gel, Chlorhexidine Digluconate 7.1%, by a Nigerian pharmaceutical company, Drugfield Pharmaceuticals Ltd.
With use of low-cost antiseptic, chlorhexidine, the country has lowered the risk of death in newborn babies by 23 percent.
“The scale-up plan, currently being implemented, aims to make chlorhexidine available in over three-fourths of Nepal’s districts by the end of 2015.”
Save the Children wants developing countries to increase health expenditure to the World Health Organisation minimum of £40 per person and remove all fees for maternity and newborn care.
This year’s most notable achievements in the field of child health.
On December 5, 2013, the governor of Nigeria’s Bauchi State, Isa Yuguda, personally launched the state’s first misoprostol and chlorhexidine (CHX) program.
Since its inception in 1988, the FCHV programme has proven to be a key factor in Nepal’s dramatic reduction in maternal and child mortality.
WHO’s decision to include the product is an important step in encouraging its introduction for umbilical cord care in low-resource settings worldwide.
“If we really want to drive down child mortality overall, we have to move that newborn number faster,” says Carolyn Miles, president and CEO of Save the Children.
Grand Challenges Canada announced $10.9 million in seed money to that will part go to help combat newborn infections and prematurity.